Global Blood Therapeutics Inc. is developing a small molecule that allosterically binds to hemoglobin and could be a disease-modifying treatment for sickle cell disease.
The product could provide an alternative to the only cure - bone marrow transplant - as well as to Phase III candidates that are seeking to reduce the duration or frequency of vaso-occlusive crisis. These acute pain crises are caused when sickled red blood cells block vessels, and usually require hospitalization and narcotics.
"We're not trying to treat crisis. We're trying to